Search Results - Collaboration+Sought+%3e+Collaboration

608 Results

Sort By:

Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration

Description of Technology: Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS...

Published: 4/16/2026 | Updated: 4/16/2026 | Inventor(s): Wei Li, Jingxing Ou, Tantai Zhao

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Neurology, Collaboration Sought > Licensing

DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen. This technology encompasses a DNA methylation–based diagnostic platform designed to improve the accuracy and consistency of cancer classification,...

Published: 4/23/2026 | Updated: 4/10/2026 | Inventor(s): Kenneth Aldape, Ziedulla Abdullaev, Rustamzhon Turakulov, Stefania Pittaluga, Mark Raffeld, Elaine Jaffe, Omkar Singh, Antonios Papanicolau-Sengos

Keywords(s):

Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia

Summary: The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. Description of Technology: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis...

Published: 4/10/2026 | Updated: 4/10/2026 | Inventor(s): Vid Leko, Aidan Pursley, Kenichi Hanada, Zhiya Yu, Catherine Ade, James Yang

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis...

Published: 3/24/2026 | Updated: 3/13/2026 | Inventor(s): S. Patricia Becerra, Alexandra Bernardo-Colon, Valeria Marigo, Andrea Bighinati

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images. Description of Technology: The present disclosure generally relates a method of automatically...

Published: 4/23/2026 | Updated: 3/11/2026 | Inventor(s): Wathudurage De Silva, Catherine Cukras

Keywords(s):

Category(s): Application > Software / Apps, TherapeuticArea, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases...

Published: 3/11/2026 | Updated: 3/11/2026 | Inventor(s): S. Patricia Becerra, Rolf Swenson, Natarajan Raju, Alexandra Bernardo-Colon, Carolyn Woodroofe, Burchelle Blackman

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Real-time AI System for Echocardiography Analysis and Quantification

Summary: We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. Description of Technology: Scientists have developed an artificial intelligence (AI) system to automatically extract predictive biomarkers from echocardiography. This AI system...

Published: 2/18/2026 | Updated: 2/18/2026 | Inventor(s): Ghada Alzamzmi, Sameer Antani, Li-Yueh Hsu, Vandana Sachdev, Sivarama Krishnan Rajaraman

Keywords(s):

Category(s): Application > Diagnostics, TherapeuticArea > Cardiology, Collaboration Sought > Collaboration, Application > Software / Apps

Humanized 40H3 Antibody

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Updated: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Humanized Monoclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer...

Published: 2/11/2026 | Updated: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

1 2 3 4 5 6 7 8 9 10 ...